

- Scoccianti S, Ricardi U. Treatment of brain metastases: Review of phase III randomized controlled trials. *Radiother Oncol* 2012;102:168–179.
- Johnson JD, Young B. Demographics of brain metastasis. *Neurosurg Clin N Am* 1996;7:337–344.
- Schouten LJ, Rutten J, Huvencers HA, et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. *Cancer* 2002;94:2698–2705.
- Lohr F, Pirzkall A, Hof H, et al. Adjuvant treatment of brain metastases. *Semin Surg Oncol* 2001;20:50–56.
- Nussbaum ES, Djalilian HR, Cho KH, et al. Brain metastases. Histology, multiplicity, surgery, and survival. *Cancer* 1996;78:1781–1788.
- Mehta MP, Rodrigus P, Terhaard CH, et al. Survival and neurologic outcomes in a randomized trial of metoprolol and whole-brain radiation therapy in brain metastases. *J Clin Oncol* 2003;21:2529–2536.
- Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and metoprolol: Results of a randomized phase III trial. *J Clin Oncol* 2004;22:157–165.
- Chang EL, Wefel JS, Maor MH, et al. A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. *Neurosurgery* 2007;60:277–283, discussion 283–284.
- Li J, Bentzen SM, Renschler M, et al. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. *J Clin Oncol* 2007;25:1260–1266.
- Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. *J Neurooncol* 1999;44:275–281.
- Yuh WT, Fisher DJ, Runge VM, et al. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases. *AJNR Am J Neuroradiol* 1994;15:1037–1051.
- Hwang TL, Close TP, Grego JM, et al. Predilection of brain metastasis in gray and white matter junction and vascular border zones. *Cancer* 1996;77:1551–1555.
- Kruger S, Mottaghy FM, Buck AK, et al. Brain metastasis in lung cancer. Comparison of cerebral MRI and 18F-FDG-PET/CT for diagnosis in the initial staging. *Nuklearmedizin* 2011;50:101–106.
- Patel TR, McHugh BJ, Bi WL, et al. A comprehensive review of MR imaging changes following radiosurgery to 500 brain metastases. *AJNR Am J Neuroradiol* 2011;32:1885–1892.
- Chapman CH, Nazem-Zadeh M, Lee OE, et al. Regional variation in brain white matter diffusion index changes following chemoradiotherapy: A prospective study using tract-based spatial statistics. *PLoS One* 2013;8:e57768.
- Lin NU, Lee EQ, Aoyama H, et al. Challenges relating to solid tumour brain metastases in clinical trials, part 1: Patient population, response, and progression. A report from the RANO group. *Lancet Oncol* 2013;14:e396–e406.
- Lin NU, Wefel JS, Lee EQ, et al. Challenges relating to solid tumour brain metastases in clinical trials, part 2: Neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. *Lancet Oncol* 2013;14:407–416.
- Therasse P, Arbusk SC, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 2000;92:205–216.
- Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *Eur J Cancer* 2009;45:228–247.
- Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. *Cancer* 1981;47:207–214.
- Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. *J Clin Oncol* 1990;8:1277–1280.
- Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. *J Clin Oncol* 2010;28:1963–1972.
- Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. *Int J Radiat Oncol Biol Phys* 1997;37:745–751.
- Sperduto PW, Berkey B, Gaspar LE, et al. A new prognostic index and comparison to three other indices for patients with brain metastases: An analysis of 1,960 patients in the RTOG database. *Int J Radiat Oncol Biol Phys* 2008;70:510–514.
- Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. *J Clin Oncol* 2012;30:419–425.
- Sperduto PW, Kased N, Roberge D, et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. *Int J Radiat Oncol Biol Phys* 2012;82:2111–2117.
- Barnholtz-Sloan JS, Yu C, Sloan AE, et al. A nomogram for individualized estimation of survival among patients with brain metastasis. *Neuro Oncol* 2012;14:910–918.
- Vecht CJ, Hovestadt A, Verbiest HB, et al. Dose-effect relationship of dexamethasone on karnofsky performance in metastatic brain tumors: A randomized study of doses of 4, 8, and 16 mg per day. *Neurology* 1994;44:675–680.
- Gaspar LE, Gutin PH, Rogers L, et al. Pre-irradiation evaluation and management of brain metastases. American College of Radiology. ACR Appropriateness Criteria. *Radiology* 2000;215:1105–1110.
- Hempfen C, Weiss E, Hess CF. Dexamethasone treatment in patients with brain metastases and primary brain tumors: Do the benefits outweigh the side-effects? *Support Care Cancer* 2002;10:322–328.
- Soffiotti R, Cornu P, Delattre JY, et al. EFNS guidelines on diagnosis and treatment of brain metastases: Report of an EFNS task force. *Eur J Neurol* 2006;13:674–681.
- Brainin M, Barnes M, Baron J, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces—revised recommendations 2004. *Eur J Neurol* 2004;11:577–581.
- Ryken TC, McDermott M, Robinson PD, et al. The role of steroids in the management of brain metastases: A systematic review and evidence-based clinical practice guideline. *J Neurooncol* 2010;96:103–114.
- Arnold SM, Patchell RA. Diagnosis and management of brain metastases. *Hematol Oncol Clin North Am* 2001;15:1085–1107, vii.
- Mikkelsen T, Paleologos NA, Robinson PD, et al. The role of prophylactic anticonvulsants in the management of brain metastases: A systematic review and evidence-based clinical practice guideline. *J Neurooncol* 2010;96:97–102.
- Forsyth PA, Weaver S, Fulton D, et al. Prophylactic anticonvulsants in patients with brain tumour. *Can J Neurol Sci* 2003;30:106–112.
- Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2000;54:1886–1893.
- Perry J, Zimman L, Chambers A, et al. The use of prophylactic anticonvulsants in patients with brain tumours—a systematic review. *Curr Oncol* 2006;13:222–229.
- Vern-Gross TZ, Kowal-Vern A. Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis syndrome in patients undergoing radiation therapy: A literature review. *Am J Clin Oncol* 2012 [Epub ahead of print].
- Wu AS, Trinh VT, Suki D, et al. A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors. *J Neurosurg* 2013;118:873–883.
- Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol* 2013;31:2189–2204.
- Lyman GH. Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. *Cancer* 2009;115:5637–5650.
- PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: The PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. *Circulation* 2005;112:416–422.
- Suh JH. Stereotactic radiosurgery for the management of brain metastases. *N Engl J Med* 2010;362:1119–1127.
- Suh JH, Videtic GM, Aref AM, et al. ACR appropriateness criteria: Single brain metastasis. *Curr Probl Cancer* 2010;34:162–174.
- Expert Panel on Radiation Oncology-Brain Metastases, Videtic GM, Gaspar LE, et al. American College of Radiology appropriateness criteria on multiple brain metastases. *Int J Radiat Oncol Biol Phys* 2009;75:961–965.
- Nabors LB, Ammirati M, Bierman PJ, et al. Central nervous system cancers. *J Natl Compr Canc Netw* 2013;11:1114–1151.
- Gaspar LE, Mehta MP, Patchell RA, et al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. *J Neurooncol* 2010;96:17–32.
- Kalkanis SN, Kondziolka D, Gaspar LE, et al. The role of surgical resection in the management of newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. *J Neurooncol* 2010;96:33–43.
- Linskey ME, Andrews DW, Asher AL, et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. *J Neurooncol* 2010;96:45–68.
- Chao JH, Phillips R, Nickson JJ. Roentgen-ray therapy of cerebral metastases. *Cancer* 1954;7:682–689.
- Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: Final results of the first two studies by the Radiation Therapy Oncology Group. *Int J Radiat Oncol Biol Phys* 1980;6:1–9.
- Borgelt B, Gelber R, Larson M, et al. Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: Final results of the first two studies by the Radiation Therapy Oncology Group. *Int J Radiat Oncol Biol Phys* 1981;7:1633–1638.
- Kurtz JM, Gelber R, Brady LW, et al. The palliation of brain metastases in a favorable patient population: A randomized clinical trial by the Radiation Therapy Oncology Group. *Int J Radiat Oncol Biol Phys* 1981;7:891–895.
- Murray KJ, Scott C, Greenberg HM, et al. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: A report of the Radiation Therapy Oncology Group (RTOG) 9104. *Int J Radiat Oncol Biol Phys* 1997;39:571–574.

56. Tsao MN, Rades D, Wirth A, et al. International practice survey on the management of brain metastases: Third international consensus workshop on palliative radiotherapy and symptom control. *Clin Oncol (R Coll Radiol)* 2012;24:81–92.
57. Kondziolka D, Patel A, Lunsford LD, et al. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. *Int J Radiat Oncol Biol Phys* 1999;45:427–434.
58. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. *Lancet* 2004;363:1665–1672.
59. Nieder C, Berberich W, Schnabel K. Tumor-related prognostic factors for remission of brain metastases after radiotherapy. *Int J Radiat Oncol Biol Phys* 1997;39:25–30.
60. Nieder C, Nestle U, Walter K, et al. Dose/effect relationships for brain metastases. *J Cancer Res Clin Oncol* 1998;124:346–350.
61. Gondi V, Mehta M, Pugh S. Memory preservation with conformal avoidance of the hippocampus during whole-brain radiotherapy (WBRT) for patients with brain metastases: Primary endpoint results of RTOG 0933. *Plenary Session of ASTRO 2013, Atlanta, Georgia, Late Breaking Abstract* 2013.
62. Brown PD, Pugh S, Laack NN, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: A randomized, double-blind, placebo-controlled trial. *Neuro Oncol* 2013;15:1429–1437.
63. Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. *N Engl J Med* 1999;341:476–484.
64. Meert AP, Paesmans M, Berghmans T, et al. Prophylactic cranial irradiation in small cell lung cancer: A systematic review of the literature with meta-analysis. *BMC Cancer* 2001;1:5.
65. Le Pechoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): A randomised clinical trial. *Lancet Oncol* 2009;10:467–474.
66. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. *N Engl J Med* 2007;357:664–672.
67. Arriagada R. Re: Prophylactic cranial irradiation for patients with small-cell lung cancer. *J Natl Cancer Inst* 1995;87:766.
68. Gregor A, Cull A, Stephens RJ, et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: Results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for Research and Treatment of Cancer (EORTC). *Eur J Cancer* 1997;33:1752–1758.
69. Gore EM, Bae K, Wong SJ, et al. Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: Primary analysis of Radiation Therapy Oncology Group study RTOG 0214. *J Clin Oncol* 2011;29:272–278.
70. Gondi V, Paulus R, Bruner DW, et al. Decline in tested and self-reported cognitive functioning after prophylactic cranial irradiation for lung cancer: Pooled secondary analysis of Radiation Therapy Oncology Group randomized trials 0212 and 0214. *Int J Radiat Oncol Biol Phys* 2013;86:656–664.
71. Mehta MP, Shapiro WR, Phan SC, et al. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: Results of a phase III trial. *Int J Radiat Oncol Biol Phys* 2009;73:1069–1076.
72. Suh JH, Stea B, Nabid A, et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. *J Clin Oncol* 2006;24:106–114.
73. Suh J, Stea B, Tankel K, et al. Results of the phase III ENRICH (RT-016) study of efaproxiral administered concurrent with whole brain radiation therapy (WBRT) in women with brain metastases from breast cancer. *Int J Rad Oncol Biol Phys* 2008;72:S50.
74. Knisely JP, Berkey B, Chakravarti A, et al. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). *Int J Radiat Oncol Biol Phys* 2008;71:79–86.
75. Vogelbaum MA, Suh JH. Resectable brain metastases. *J Clin Oncol* 2006;24:1289–1294.
76. Patel AJ, Suki D, Hatiboglu MA, et al. Factors influencing the risk of local recurrence after resection of a single brain metastasis. *J Neurosurg* 2010;113:181–189.
77. Suki D, Abouassi H, Patel AJ, et al. Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa. *J Neurosurg* 2008;108:248–257.
78. Suki D, Hatiboglu MA, Patel AJ, et al. Comparative risk of leptomeningeal dissemination of cancer after surgery or stereotactic radiosurgery for a single supratentorial solid tumor metastasis. *Neurosurgery* 2009;64:664–674.
79. Siomin VE, Vogelbaum MA, Kanner AA, et al. Posterior fossa metastases: Risk of leptomeningeal disease when treated with stereotactic radiosurgery compared to surgery. *J Neurooncol* 2004;67:115–121.
80. Bindal RK, Sawaya R, Leavens ME, et al. Surgical treatment of multiple brain metastases. *J Neurosurg* 1993;79:210–216.
81. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. *N Engl J Med* 1990;322:494–500.
82. Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. *Int J Radiat Oncol Biol Phys* 1994;29:711–717.
83. Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. *Cancer* 1996;78:1470–1476.
84. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. *JAMA* 1998;280:1485–1489.
85. Patchell RA, Regine WF. The rationale for adjuvant whole brain radiation therapy with radiosurgery in the treatment of single brain metastases. *Technol Cancer Res Treat* 2003;2:111–115.
86. Kocher M, Soffiotti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study. *J Clin Oncol* 2011;29:134–141.
87. Leksell L. The stereotaxic method and radiosurgery of the brain. *Acta Chir Scand* 1951;102:316–319.
88. Flickinger JC, Kondziolka D, Lunsford LD, et al. A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. *Int J Radiat Oncol Biol Phys* 1994;28:797–802.
89. Likhacheva A, Pinnix CC, Parikh NR, et al. Predictors of survival in contemporary practice after initial radiosurgery for brain metastases. *Int J Radiat Oncol Biol Phys* 2013;85:656–661.
90. Karlsson B, Hanssens P, Wolff R, et al. Thirty years' experience with gamma knife surgery for metastases to the brain. *J Neurosurg* 2009;111:449–457.
91. Serizawa T, Hirai T, Nagano O, et al. Gamma knife surgery for 1-10 brain metastases without prophylactic whole-brain radiation therapy: Analysis of cases meeting the Japanese prospective multi-institute study (JLGK0901) inclusion criteria. *J Neurooncol* 2010;98:163–167.
92. Sheehan JP, Yen CP, Nguyen J, et al. Timing and risk factors for new brain metastasis formation in patients initially treated only with gamma knife surgery. Clinical article. *J Neurosurg* 2011;114:763–768.
93. Goodman KA, Sneed PK, McDermott MW, et al. Relationship between pattern of enhancement and local control of brain metastases after radiosurgery. *Int J Radiat Oncol Biol Phys* 2001;50:139–146.
94. Shiau CY, Sneed PK, Shu HK, et al. Radiosurgery for brain metastases: Relationship of dose and pattern of enhancement to local control. *Int J Radiat Oncol Biol Phys* 1997;37:375–383.
95. Brown PD, Brown CA, Pollock BE, et al. Stereotactic radiosurgery for patients with “radioresistant” brain metastases. *Neurosurgery* 2002;51:656–665, discussion 665–667.
96. Chang EL, Selek U, Hassenbusch SJ 3rd, et al. Outcome variation among “radioresistant” brain metastases treated with stereotactic radiosurgery. *Neurosurgery* 2005;56:936–945, discussion 936–945.
97. Hunter GK, Suh JH, Reuther AM, et al. Treatment of five or more brain metastases with stereotactic radiosurgery. *Int J Radiat Oncol Biol Phys* 2012;83:1394–1398.
98. Yamamoto M, Kawabe T, Sato Y, et al. A case-matched study of stereotactic radiosurgery for patients with multiple brain metastases: Comparing treatment results for 1-4 vs ≥ 5 tumors: Clinical article. *J Neurosurg* 2013;118:1258–1268.
99. Grandhi R, Kondziolka D, Panczykowski D, et al. Stereotactic radiosurgery using the leksell gamma knife perfexion unit in the management of patients with 10 or more brain metastases. *J Neurosurg* 2012;117:237–245.
100. Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05. *Int J Radiat Oncol Biol Phys* 2000;47:291–298.
101. Vogelbaum MA, Angelov L, Lee SY, et al. Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin. *J Neurosurg* 2006;104:907–912.
102. Yomo S, Hayashi M, Nicholson C. A prospective pilot study of two-session Gamma Knife surgery for large metastatic brain tumors. *J Neurooncol* 2012;109:159–165.
103. Prabhu RS, Dhabaan A, Hall WA, et al. Clinical outcomes for a novel 6 degrees of freedom image guided localization method for frameless radiosurgery for intracranial brain metastases. *J Neurooncol* 2013;113:93–99.
104. Pan H, Cervino LI, Pawlicki T, et al. Frameless, real-time, surface imaging-guided radiosurgery: Clinical outcomes for brain metastases. *Neurosurgery* 2012;71:844–851.
105. Nath SK, Lawson JD, Simpson DR, et al. Single-isocenter frameless intensity-modulated stereotactic radiosurgery for simultaneous treatment of multiple brain metastases: Clinical experience. *Int J Radiat Oncol Biol Phys* 2010;78:91–97.
106. Muacevic A, Kufeld M, Wowra B, et al. Feasibility, safety, and outcome of frameless image-guided robotic radiosurgery for brain metastases. *J Neurooncol* 2010;97:267–274.
107. Breneman JC, Steinmetz R, Smith A, et al. Frameless image-guided intracranial stereotactic radiosurgery: Clinical outcomes for brain metastases. *Int J Radiat Oncol Biol Phys* 2009;74:702–706.
108. Oermann EK, Kress MA, Todd JV, et al. The impact of radiosurgery fractionation and tumor radiobiology on the local control of brain metastases. *J Neurosurg* 2013;119:1131–1138.

109. Chao ST, Ahluwalia MS, Barnett GH, et al. Challenges with the diagnosis and treatment of cerebral radiation necrosis. *Int J Radiat Oncol Biol Phys* 2013;87:449–457.
110. Stockham AL, Ahluwalia M, Reddy CA, et al. Results of a questionnaire regarding practice patterns for the diagnosis and treatment of intracranial radiation necrosis after SRS. *J Neurooncol* 2013;115:469–475.
111. Mitsuya K, Nakasu Y, Horiguchi S, et al. Perfusion weighted magnetic resonance imaging to distinguish the recurrence of metastatic brain tumors from radiation necrosis after stereotactic radiosurgery. *J Neurooncol* 2010;99:81–88.
112. Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. *Int J Radiat Oncol Biol Phys* 2011;79:1487–1495.
113. Rahmathulla G, Recinos PF, Valerio JE, et al. Laser interstitial thermal therapy for focal cerebral radiation necrosis: A case report and literature review. *Stereotact Funct Neurosurg* 2012;90:192–200.
114. Loeffler JS, Shrieve DC. What is appropriate therapy for a patient with a single brain metastasis? *Int J Radiat Oncol Biol Phys* 1994;29:915–917, discussion 920.
115. Mucevic A, Kreth FW, Horstmann GA, et al. Surgery and radiotherapy compared with gamma knife radiosurgery in the treatment of solitary cerebral metastases of small diameter. *J Neurosurg* 1999;91:35–43.
116. Lang FF, Suki D, Maor M, et al. Conventional surgery versus stereotactic radiosurgery in the treatment of single brain metastases: A prospective study with both randomized and nonrandomized arms. American Association of Neurological Surgeons (abstract). 2008.
117. Lang RF. Personal communication with author.
118. Sperduto PW, Wang M, Robins HI, et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. *Int J Radiat Oncol Biol Phys* 2013;85:1312–1318.
119. Brown PD, Asher AL, Farace E. Adjuvant whole brain radiotherapy: Strong emotions decide but rational studies are needed. *Int J Radiat Oncol Biol Phys* 2008;70:1305–1309.
120. Sneed PK, Lamborn KR, Forstner JM, et al. Radiosurgery for brain metastases: Is whole brain radiotherapy necessary? *Int J Radiat Oncol Biol Phys* 1999;43:549–558.
121. Sneed PK, Suh JH, Goetsch SJ, et al. A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. *Int J Radiat Oncol Biol Phys* 2002;53:519–526.
122. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. *JAMA* 2006;295:2483–2491.
123. Aoyama H, Tago M, Kato N, et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. *Int J Radiat Oncol Biol Phys* 2007;68:1388–1395.
124. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial. *Lancet Oncol* 2009;10:1037–1044.
125. Lal LS, Byfield SD, Chang EL, et al. Cost-effectiveness analysis of a randomized study comparing radiosurgery with radiosurgery and whole brain radiation therapy in patients with 1 to 3 brain metastases. *Am J Clin Oncol* 2012;35:45–50.
126. Roberge D, Parney I, Brown PD. Radiosurgery to the postoperative surgical cavity: Who needs evidence? *Int J Radiat Oncol Biol Phys* 2012;83:486–493.
127. Gans JH, Raper DM, Shah AH, et al. The role of radiosurgery to the tumor bed after resection of brain metastases. *Neurosurgery* 2013;72:317–325, discussion 325–326.
128. Choi CY, Chang SD, Gibbs IC, et al. Stereotactic radiosurgery of the postoperative resection cavity for brain metastases: Prospective evaluation of target margin on tumor control. *Int J Radiat Oncol Biol Phys* 2012;84:336–342.
129. Atalar B, Choi CY, Harsh GR 4th, et al. Cavity volume dynamics after resection of brain metastases and timing of postresection cavity stereotactic radiosurgery. *Neurosurgery* 2013;72:180–185, discussion 185.
130. Atalar B, Modlin LA, Choi CY, et al. Risk of leptomeningeal disease in patients treated with stereotactic radiosurgery targeting the postoperative resection cavity for brain metastases. *Int J Radiat Oncol Biol Phys* 2013;87:713–718.
131. Curry WT Jr, Cosgrove GR, Hochberg FH, et al. Stereotactic interstitial radiosurgery for cerebral metastases. *J Neurosurg* 2005;103:630–635.
132. Pantazis G, Trippel M, Birg W, et al. Stereotactic interstitial radiosurgery with the Photon Radiosurgery System (PRS) for metastatic brain tumors: A prospective single-center clinical trial. *Int J Radiat Oncol Biol Phys* 2009;75:1392–1400.
133. Rogers LR, Rock JP, Sills AK, et al. Results of a phase II trial of the GliaSite radiation therapy system for the treatment of newly diagnosed, resected single brain metastases. *J Neurosurg* 2006;105:375–384.
134. Chao ST, Barnett GH, Vogelbaum MA, et al. Salvage stereotactic radiosurgery effectively treats recurrences from whole-brain radiation therapy. *Cancer* 2008;113:2198–2204.
135. Abdel-Wahab MM, Wolfson AH, Raub W, et al. The role of hyperfractionated re-irradiation in metastatic brain disease: A single institutional trial. *Am J Clin Oncol* 1997;20:158–160.
136. Cooper JS, Steinfeld AD, Lerch IA. Cerebral metastases: Value of reirradiation in selected patients. *Radiology* 1990;174:883–885.
137. Wong WW, Schild SE, Sawyer TE, et al. Analysis of outcome in patients reirradiated for brain metastases. *Int J Radiat Oncol Biol Phys* 1996;34:585–590.
138. Bindal RK, Sawaya R, Leavens ME, et al. Reoperation for recurrent metastatic brain tumors. *J Neurosurg* 1995;83:600–604.
139. Muldoon LL, Soussain C, Jahnke K, et al. Chemotherapy delivery issues in central nervous system malignancy: A reality check. *J Clin Oncol* 2007;25:2295–2305.
140. Neuwelt EA. Mechanisms of disease: The blood-brain barrier. *Neurosurgery* 2004;54:131–140, discussion 141–142.
141. Patel M, McCully C, Godwin K, et al. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. *J Neurooncol* 2003;61:203–207.
142. Gril B, Palmieri D, Bronder JL, et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. *J Natl Cancer Inst* 2008;100:1092–1103.
143. Taskar KS, Rudraraju V, Mittapalli RK, et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. *Pharm Res* 2012;29:770–781.
144. Clarke JL, Pao W, Wu N, et al. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. *J Neurooncol* 2010;99:283–286.
145. Mandula H, Parepally JM, Feng R, et al. Role of site-specific binding to plasma albumin in drug availability to brain. *J Pharmacol Exp Ther* 2006;317:667–675.
146. Caffo M, Barresi V, Caruso G, et al. Innovative therapeutic strategies in the treatment of brain metastases. *Int J Mol Sci* 2013;14:2135–2174.
147. Breedveld P, Plum D, Cipriani G, et al. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. *Cancer Res* 2005;65:2577–2582.
148. Vogelbaum MA. Convection enhanced delivery for the treatment of malignant gliomas: Symposium review. *J Neurooncol* 2005;73:57–69.
149. Bratlid D, Moe PJ. Pharmacokinetics of high-dose methotrexate treatment in children. *Eur J Clin Pharmacol* 1978;14:143–147.
150. Bachmann C, Grischke EM, Staehler A, et al. Receptor change-clinicopathologic analysis of matched pairs of primary and cerebral metastatic breast cancer. *J Cancer Res Clin Oncol* 2013;139:1909–1916.
151. Franciosi V, Cocconi G, Michiara M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: A prospective study. *Cancer* 1999;85:1599–1605.
152. Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. *Cancer* 1986;58:832–839.
153. Lassman AB, Abrey LE, Shah GD, et al. Systemic high-dose intravenous methotrexate for central nervous system metastases. *J Neurooncol* 2006;78:255–260.
154. Lin NU, Eierman W, Greil R, et al. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. *J Neurooncol* 2011;105:613–620.
155. Gril B, Palmieri D, Qian Y, et al. Pazopanib reveals a role for tumor cell B-raf in the prevention of HER2+ breast cancer brain metastasis. *Clin Cancer Res* 2011;17:142–153.
156. Preusser M, Berghoff AS, Schandendorf D, et al. Brain metastasis: Opportunity for drug development? *Curr Opin Neurol* 2012;25:786–794.
157. Drappatz J, Batchelor TT. Leptomeningeal neoplasms. *Curr Treat Options Neurol* 2007;9:283–293.
158. Jorda M, Ganjei-Azar P, Nadjmi M. Cytologic characteristics of meningeal carcinomatosis: Increased diagnostic accuracy using carcinoembryonic antigen and epithelial membrane antigen immunocytochemistry. *Arch Neurol* 1998;55:181–184.
159. Chamberlain MC. CSF disseminated primary brain tumors. In Newton HB, ed. *Handbook of Brain Tumor Chemotherapy*. Amsterdam: Elsevier Science; 2005:316.
160. Glass JP, Melamed M, Chernik NL, et al. Malignant cells in cerebrospinal fluid (CSF): The meaning of a positive CSF cytology. *Neurology* 1979;29:1369–1375.
161. Van Horn A, Chamberlain MC. Neoplastic meningitis. *J Support Oncol* 2012;10:45–53.
162. Oechsle K, Lange-Brock V, Kruell A, et al. Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: A retrospective analysis. *J Cancer Res Clin Oncol* 2010;136:1729–1735.
163. Chamberlain MC. Neoplastic meningitis: A guide to diagnosis and treatment. *Curr Opin Neurol* 2000;13:641–648.
164. Clarke JL, Perez HR, Jacks LM, et al. Leptomeningeal metastases in the MRI era. *Neurology* 2010;74:1449–1454.
165. Chamberlain MC. Cytologically negative carcinomatous meningitis: Usefulness of CSF biochemical markers. *Neurology* 1998;50:1173–1175.

166. Quijano S, Lopez A, Manuel Sancho J, et al. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin lymphoma: Improved sensitivity of flow cytometry. *J Clin Oncol* 2009;27:1462–1469.
167. Glantz MJ, Cole BF, Recht L, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: Is intrathecal chemotherapy necessary? *J Clin Oncol* 1998;16:1561–1567.
168. Ahluwalia MS, Wallace PK, Peereboom DM. Flow cytometry as a diagnostic tool in lymphomatous or leukemic meningitis: Ready for prime time? *Cancer* 2012;118:1747–1753.
169. Lombardi G, Zustovich F, Farina P, et al. Neoplastic meningitis from solid tumors: New diagnostic and therapeutic approaches. *Oncologist* 2011;16:1175–1188.
170. Bleyer WA, Fallavollita J, Robison L, et al. Influence of age, sex, and concurrent intrathecal methotrexate therapy on intellectual function after cranial irradiation during childhood: A report from the Children's Cancer Study Group. *Pediatr Hematol Oncol* 1990;7:329–338.
171. Motl S, Zhuang Y, Waters CM, et al. Pharmacokinetic considerations in the treatment of CNS tumours. *Clin Pharmacokinet* 2006;45:871–903.
172. Gabay MP, Thakkar JP, Stachnik JM, et al. Intra-CSF administration of chemotherapy medications. *Cancer Chemother Pharmacol* 2012;70:1–15.
173. Larson DA, Rubenstein JL, McDermott MW, et al. Metastatic cancer to the brain. In DeVita VT, Lawrence TS, Rosenberg SA, eds. *Cancer: Principles & Practices of Oncology*. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011:2160.